Experience the world of KURIOS – Cabinet of Curiosities like never before with Parallel!, an interactive digital platform that lets viewers explore backstage, follow performers, and navigate the show for total immersion.
MONTREAL, April 15, 2025 /PRNewswire/ -- Cirque du Soleil Entertainment Group ("Cirque du Soleil" or "the company"), in collaboration with Imagien, the company behind the interactive digital platform Parallel!, is excited to announce the launch of KURIOS - cabinet of Curiosities - In Parallel!. This groundbreaking digital format offers viewers behind-the-scenes access, parallel storylines, and a curated selection of stunning content, making them feel as if they were truly part of the show!
With this new format, friends and family can watch the show together while controlling their own experience and sharing the excitement in real time. By combining their TVs, phones, and tablets, fans unlock an interactive experience that transforms how they watch. It becomes a dynamic, social way to enjoy the show, where everyone can explore different aspects simultaneously.
"Our goal was to create the best possible experience, recognizing the importance of testing the market and understanding how fans would embrace this new offering. The overwhelmingly positive response has reinforced our commitment to delivering a seamless, user-friendly experience that brings the magic of Cirque du Soleil into homes around the world. By seamlessly blending technology, storytelling, and real-time interaction, we are redefining how fans experience Cirque du Soleil—not just as spectators, but as active participants in our universe. With significant effort and innovation, we've ensured that audiences can enjoy it anytime, anywhere, with ease and excitement. And this is just the beginning of a deeper, more meaningful connection with our audience—every day of the year", says Anne Belliveau, Chief Customer Experience Officer at Cirque du Soleil Entertainment Group.
Even before watching the main stage show, viewers can explore the venue in a whole new way. They can visit the VIP area, go backstage to see performers preparing, and witness the detailed work that brings the spectacle to life. Viewers can follow different characters, use an interactive map to navigate through locations, and explore multiple areas of the venue, offering them exclusive access like never before.
For the company, KURIOS - cabinet of Curiosities - In Parallel! marks a pivotal point in how they expand their reach globally and draw new fans to the brand. "It truly aligns with our commitment to bringing Cirque du Soleil into people's daily lives and encouraging them to attend our Big Top shows when they come to their city" says Anne Belliveau. This new interactive experience in collaboration with Imagien perfectly embodies our vision of going beyond the stage by offering fans our beloved intellectual properties in various formats, available whenever they want" she adds.
The company is currently engaged in active discussions with Imagien to bring viewers more iconic shows from its portfolio in this format and to strengthen its presence in markets across the globe.
"We are proud to partner with Cirque du Soleil and provide the technology and platform behind this revolutionary interactive experience. We are looking forward to supporting Cirque du Soleil as they continue to grow and bring their iconic performances to audiences worldwide" says Danny Theis, CEO of Imagien.
KURIOS - cabinet of Curiosities - In Parallel! is now available for purchase in select markets at https://event.imagien.com/kurios
About Cirque du Soleil Entertainment Group
Cirque du Soleil Entertainment Group is a world leader in live entertainment. Building on four decades of pushing the boundaries of the imagination, the artistic entertainment company brings its creative approach to a large variety of artistic forms such as live shows, multimedia productions, long-form content, music, immersive experiences, and special events. Since its creation in 1984, more than 400 million people have been inspired on 6 continents and 86 countries. The Canadian company now employs almost 4000 employees, including 1200 artists from more than 80 different nationalities. Along with its affiliates—Blue Man Group, VStar Entertainment Group, and The Works Entertainment—Cirque du Soleil Entertainment Group continues to expand its creative reach. For more information about Cirque du Soleil Entertainment Group, please visit http://www.cirquedusoleil.com.
About Imagien
Imagien, in partnership with world-class entertainment leaders, is transforming the industry by bringing live events into the home. Through its innovative platform and technology, Imagien enables rights holders to turn their live shows into immersive, interactive experiences for audiences at home. By collaborating with rights holders, producers, promoters, and the entertainment industry, Imagien is leading the future of in-home entertainment - delivering live performances to millions of people around the world - all from the comfort of their homes. For more information about Imagien, please visit imagien.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
CIRQUE DU SOLEIL INTRODUCES NEW INTERACTIVE DIGITAL EXPERIENCE, OFFERING BACKSTAGE ACCESS TO FANS
|
OXFORD, United Kingdom and HOUSTON, June 5, 2026 /PRNewswire/ -- Optellum, a leader in AI-enabled lung cancer diagnostics, today announced that it has surpassed 250 clinical sites and analyzed more than 3 million cases to date. This milestone underscores Optellum's commitment to empowering health systems and clinical care teams with the tools needed to identify, prioritize, and manage high-risk lung nodules more effectively. This commercial momentum is supported by first-of-their-kind partnerships across major markets, including with Bristol Myers Squibb in the US, and with the NHS and Intuitive Surgical to support end-to-end AI & robot lung cancer pathways in the UK. It is also reflected in established and new customer deployments at leading health systems, including the University of Pennsylvania Health System, Vanderbilt University Medical Center, and Oxford University Hospitals.
The scale of Optellum's impact is accelerating rapidly, and the company is now helping one patient every 14 seconds. Optellum pioneered the world's first FDA-cleared, CE-marked, and Medicare-reimbursed AI solution for image-based lung cancer risk stratification – Lung Cancer Prediction (LCP) AI, under the CPT codes 0721T and 0722T. LCP AI is helping to reduce the uncertainty associated with indeterminate lung nodules, ensuring that no nodule patient is left behind. Further, the wraparound Virtual Nodule Clinic (VNC) solution supports guideline-aligned decisions and has been shown to improve clinicians' efficiency while reducing time to recommended treatment.[1]
This growth reflects a broader shift toward the adoption of evidence-based innovation in thoracic care. Optellum continues to expand LungOSⓇ, its end-to-end AI-powered lung health platform, powered by the world's first Thorax CT Foundation Model built for real-world precision lung care. This foundation model is the only model in the world to leverage DART, the world's largest lung cancer CT dataset. LungOSⓇ brings VNC together with modules for triage and detection,[2] diagnostic support,[3] and therapy guidance.[4] Looking ahead, Optellum is poised to expand its clinical suite with the upcoming European launch of LungDetect, an exciting addition designed to simplify and accelerate nodule identification and characterization.
"Optellum is incredibly proud to be helping more health systems and clinicians provide timely, life-saving care to a growing number of patients," said Dr. Johnathan Watkins, Optellum's CEO. "Reaching 250 sites and analyzing millions of cases each year is a testament to the dedication of our team and the trust of our clinical partners. However, we are just getting started; we continue to build LungOSⓇ into the must-have "operating system" for lung cancer and thoracic care more broadly. We invite the global healthcare community to join us on our mission to help solve lung cancer by ensuring early diagnosis and early intervention become the standard for everyone everywhere."
Results from Optellum's continued growth and real-world clinical use will continue to be shared with clinicians, healthcare leaders, and policymakers to reach the broader goal of improving outcomes for every thoracic care team, in every hospital, for every patient.
About Optellum
Optellum is a commercial-stage AI healthcare company dedicated to revolutionizing early diagnosis and treatment of lung disease, starting with one of the deadliest, lung cancer.
Optellum is building LungOSⓇ, the end-to-end AI-powered platform for thoracic care. Its flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction AI (LCP), is the world's first FDA-cleared and reimbursed software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization and diagnostic support. Clinicians trust the Optellum solution to aid them in making the most appropriate life-saving treatment decisions for their patients. Backed by real-world clinical evidence, Optellum's solution accelerates the diagnostic care pathway by enabling early patient identification, enhancing prioritization, and improving clinicians' efficiency, reducing time to guideline-recommended treatment. Optellum VNC is FDA cleared, CE-MDR marked, UKCA marked, and TGA-approved.
Optellum is headquartered in Oxford, UK, and has an office in Houston, Texas, US.
[1] Hill NR et al. Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study. BMJ Open Respiratory Research. 2025;12: e003225. https://doi.org/10.1136/bmjresp-2025-003225
[2] Both text-based detection with Patient Discovery and Patient Safety Net as well as image-based detection. Product availability depends on your region, please contact Optellum for more information.
[3] Commercially available in the US, EU/UK, and Australia.
[4] Pending; for research use only
Media Contact
marketing@optellum.com
OXFORD, United Kingdom and HOUSTON, June 5, 2026 /PRNewswire/ -- Optellum, a leader in AI-enabled lung cancer diagnostics, today announced that it has surpassed 250 clinical sites and analyzed more than 3 million cases to date. This milestone underscores Optellum's commitment to empowering health systems and clinical care teams with the tools needed to identify, prioritize, and manage high-risk lung nodules more effectively. This commercial momentum is supported by first-of-their-kind partnerships across major markets, including with Bristol Myers Squibb in the US, and with the NHS and Intuitive Surgical to support end-to-end AI & robot lung cancer pathways in the UK. It is also reflected in established and new customer deployments at leading health systems, including the University of Pennsylvania Health System, Vanderbilt University Medical Center, and Oxford University Hospitals.
The scale of Optellum's impact is accelerating rapidly, and the company is now helping one patient every 14 seconds. Optellum pioneered the world's first FDA-cleared, CE-marked, and Medicare-reimbursed AI solution for image-based lung cancer risk stratification – Lung Cancer Prediction (LCP) AI, under the CPT codes 0721T and 0722T. LCP AI is helping to reduce the uncertainty associated with indeterminate lung nodules, ensuring that no nodule patient is left behind. Further, the wraparound Virtual Nodule Clinic (VNC) solution supports guideline-aligned decisions and has been shown to improve clinicians' efficiency while reducing time to recommended treatment.[1]
This growth reflects a broader shift toward the adoption of evidence-based innovation in thoracic care. Optellum continues to expand LungOSⓇ, its end-to-end AI-powered lung health platform, powered by the world's first Thorax CT Foundation Model built for real-world precision lung care. This foundation model is the only model in the world to leverage DART, the world's largest lung cancer CT dataset. LungOSⓇ brings VNC together with modules for triage and detection,[2] diagnostic support,[3] and therapy guidance.[4] Looking ahead, Optellum is poised to expand its clinical suite with the upcoming European launch of LungDetect, an exciting addition designed to simplify and accelerate nodule identification and characterization.
"Optellum is incredibly proud to be helping more health systems and clinicians provide timely, life-saving care to a growing number of patients," said Dr. Johnathan Watkins, Optellum's CEO. "Reaching 250 sites and analyzing millions of cases each year is a testament to the dedication of our team and the trust of our clinical partners. However, we are just getting started; we continue to build LungOSⓇ into the must-have "operating system" for lung cancer and thoracic care more broadly. We invite the global healthcare community to join us on our mission to help solve lung cancer by ensuring early diagnosis and early intervention become the standard for everyone everywhere."
Results from Optellum's continued growth and real-world clinical use will continue to be shared with clinicians, healthcare leaders, and policymakers to reach the broader goal of improving outcomes for every thoracic care team, in every hospital, for every patient.
About Optellum
Optellum is a commercial-stage AI healthcare company dedicated to revolutionizing early diagnosis and treatment of lung disease, starting with one of the deadliest, lung cancer.
Optellum is building LungOSⓇ, the end-to-end AI-powered platform for thoracic care. Its flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction AI (LCP), is the world's first FDA-cleared and reimbursed software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization and diagnostic support. Clinicians trust the Optellum solution to aid them in making the most appropriate life-saving treatment decisions for their patients. Backed by real-world clinical evidence, Optellum's solution accelerates the diagnostic care pathway by enabling early patient identification, enhancing prioritization, and improving clinicians' efficiency, reducing time to guideline-recommended treatment. Optellum VNC is FDA cleared, CE-MDR marked, UKCA marked, and TGA-approved.
Optellum is headquartered in Oxford, UK, and has an office in Houston, Texas, US.
[1] Hill NR et al. Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study. BMJ Open Respiratory Research. 2025;12: e003225. https://doi.org/10.1136/bmjresp-2025-003225
[2] Both text-based detection with Patient Discovery and Patient Safety Net as well as image-based detection. Product availability depends on your region, please contact Optellum for more information.
[3] Commercially available in the US, EU/UK, and Australia.
[4] Pending; for research use only
Media Contact
marketing@optellum.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Optellum Celebrates Accelerating Impact in Lung Cancer Care; Now at Over 250 Sites and Growing
